Top

Published in:

01-07-2011 | Preclinical study

Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells

Authors: Lev M. Berstein, Wei Yue, Ji-Ping Wang, Richard J. Santen

Published in: Breast Cancer Research and Treatment | Issue 1/2011

Abstract

Resistance to tamoxifen (TAM) and aromatase inhibitors represents a major drawback to the treatment of hormone-dependent breast cancer, and strategies to overcome this problem are urgently needed. The anti-diabetic biguanide metformin (MF) exerts pleiotropic effects which could enhance the effectiveness of available hormonal therapies. This study modeled several aspects of hormonal therapy in women and examined the effectiveness of MF under those conditions. For cell growth evaluation, wild-type (wt), TAM-resistant (TAM-R), and long-term estradiol-deprived (LTED) MCF-7 cells, as a model of aromatase inhibitor resistance, were grown in the presence or absence of TAM or MF for 5 days. For immunoblot analysis and aromatase activity measurements, these cells were grown for 48 h. Wild-type and LTED cells were equally sensitive to the growth inhibitory effects of TAM and MF, while TAM-R cells were less sensitive to TAM than to MF. Partial additive effects on cell number of TAM combined with MF were greatest (if compared with isolated TAM action) in TAM-R and LTED cells. In contrast to the decrease in PCNA values in TAM-resistant cells treated with the TAM and MF combination, no other changes were found in the levels of this proliferation marker. These findings suggested a major component of apoptosis in the growth inhibitory effect. This was confirmed with Western blot analysis of PARP and caspase 7 as well as with apoptosis ELISA assay. MF also altered signaling pathways. AMP-kinase was stimulated by MF approximately equally in MCF-7, TAM-R, and LTED cells, while inhibition by biguanide of p-S6K as a downstream target of mTOR was strongest in TAM-R cells. Under the influence of MF, expression of ER-α was decreased in wt MCF-7 cells suggesting possible involvement of this compound in estrogen signaling. Metformin interacts additively with TAM to reduce neoplastic cells growth. The cellular context (including loss of sensitivity to TAM and estrogen deprivation) is of importance in influencing breast cancer responses to MF and to a combination of MF and TAM.

Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, Buyse M, Baum M, Buzdar A, Colleoni M, Coombes C, Snowdon C, Gnant M, Jakesz R, Kaufmann M, Boccardo F, Godwin J, Davies C, Peto R (2010) Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus TAM. J Clin Oncol 28(3):509–518PubMedCrossRef

Giobbie-Hurder A, Price KN, Gelber RD, International Breast Cancer Study Group, BIG 1–98 Collaborative Group (2009) Design, conduct, and analyses of Breast International Group (BIG) 1–98: a randomized, double-blind, phase-III study comparing letrozole and TAM as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer. Clin Trials 6(3):272–287PubMedCrossRef

Brauch H, Jordan VC (2009) Targeting of TAM to enhance antitumour action for the treatment, prevention of breast cancer: the ‘personalised’ approach? Eur J Cancer 45(13):2274–2283PubMedCrossRef

Polin SA, Ascher SM (2008) The effect of tamoxifen on the genital tract. Cancer Imaging 8:135–145PubMedCrossRef

Musgrove EA, Sutherland RL (2009) Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9(9):631–643PubMedCrossRef

Clarke R, Liu MC, Bouker KB, Gu Z, Lee RY, Zhu Y, Skaar TC, Gomez B, O’Brien K, Wang Y, Hilakivi-Clarke LA (2003) Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 22(47):7316–7339PubMedCrossRef

Osborne CK, Shou J, Massarweh S, Schiff R (2005) Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 11(2 Pt 2):865s–870sPubMed

Gee JM, Howell A, Gullick WJ, Benz CC, Sutherland RL, Santen RJ, Martin LA, Ciardiello F, Miller WR, Dowsett M, Barrett-Lee P, Robertson JF, Johnston SR, Jones HE, Wakeling AE, Duncan R, Nicholson RI (2005) Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment. Endocr Relat Cancer Suppl 1: S1–S7

Dorssers LC, Van der Flier S, Brinkman A, van Agthoven T, Veldscholte J, Berns EM, Klijn JG, Beex LV, Foekens JA (2001) Tamoxifen resistance in breast cancer: elucidating mechanisms. Drugs 61(12):1721–1733PubMedCrossRef

10.

Santen R, Jeng MH, Wang JP, Song R, Masamura S, McPherson R, Santner S, Yue W, Shim WS (2001) Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients. J Steroid Biochem Mol Biol 79(1–5):115–125PubMedCrossRef

11.

Santen RJ, Song RX, Zhang Z, Kumar R, Jeng MH, Masamura A, Lawrence J Jr, Berstein L, Yue W (2005) Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity. Endocr Relat Cancer Suppl 1:S61–S73CrossRef

12.

Wen J, Li R, Lu Y, Shupnik MA (2009) Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor–coregulator interactions. Oncogene 28(4):575–586PubMedCrossRef

13.

Rodríguez-Enríquez S, Marín-Hernández A, Gallardo-Pérez JC, Carreño-Fuentes L, Moreno-Sánchez R (2009) Targeting of cancer energy metabolism. Mol Nutr Food Res 53(1):29–48PubMedCrossRef

14.

Berstein LM (2005) Clinical usage of hypolipidemic and antidiabetic drugs in the prevention and treatment of cancer. Cancer Lett 224(2):203–212PubMedCrossRef

15.

Libby G, Donnely LA, Donnan PT, Alessi DR, Morris AD, Evans JM (2009) New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32:1620–1625PubMedCrossRef

16.

Bodmer M, Meier Ch, Krahlenbuhl S, Jick SS, Meier CR (2010) Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 33:1304–1308PubMedCrossRef

17.

Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhinski MA, Kovalenko IG, Poroshina TE, Semenchenko AV, Provinciali M, Re F, Franceschi C (2005) Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontol 40:685–693PubMedCrossRef

18.

Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M (2006) Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66:10269–10273PubMedCrossRef

19.

Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N (2007) Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 67:10804–10812PubMedCrossRef

20.

Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, Thor AD (2009) Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 8:909–915PubMedCrossRef

21.

Zhuang Y, Miskimins WK (2008) Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. J Mol Signal 3: 18

22.

Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K (2009) Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 69(19):7507–7511PubMedCrossRef

23.

Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN, Gonzalez-Angulo AM (2009) Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27:3297–3302PubMedCrossRef

24.

Goodwin PJ, Pritchard KI, Ennis M, Clemons M, Graham M, Fantus IG (2008) Insulin-lowering effects of metformin in women with early breast cancer. Clin Breast Cancer 8:501–505PubMedCrossRef

25.

Goodwin PJ, Ligibel JA, Stambolic V (2009) Metformin in breast cancer: time for action. J Clin Oncol 27(20):3271–3273PubMedCrossRef

26.

Berstein LM (2009) Metformin, insulin, breast cancer and more. Future Oncol 5:309–312PubMedCrossRef

27.

Cazzaniga M, Bonanni B, Guerrieri-Gonzaga A, Decensi A (2009) Is it time to test metformin in breast cancer clinical trials? Cancer Epidemiol Biomarkers Prev 18:701–705PubMedCrossRef

28.

Vazquez-Martin A, Oliveras-Ferraros C, Barco SD, Martin-Castillo B, Menendez JA (2010) The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. Breast Cancer Res Treat May 11,2010 [Epub ahead of print]

29.

Metformin and cancer. http://ClinicalTrials.gov. Approached on June 30, 2010

30.

Brown KA, McInnes KJ, Hunger NI, Oakhill JS, Steinberg GR, Simpson ER (2009) Subcellular localization of cyclic AMP-responsive element binding protein-regulated transcription coactivator 2 provides a link between obesity and breast cancer in postmenopausal women. Cancer Res 69:5392–5399PubMedCrossRef

31.

Masamura S, Santner SJ, Heitjan DF, Santen RJ (1995) Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab 80(10):2918–2925PubMedCrossRef

32.

Yue W, Fan P, Wang J, Li Y, Santen RJ (2007) Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells. J Steroid Biochem Mol Biol 106:102–110PubMedCrossRef

33.

Berstein LM, Zheng H, Yue W, Wang JP, Lykkesfeldt AE, Naftolin F, Harada H, Shanabrough M, Santen RJ (2003) New approaches to the understanding of tamoxifen action and resistance. Endocr Relat Cancer 10(2):267–277PubMedCrossRef

34.

Brown KA, Hunger NI, Docanto M, Simpson ER (2010) Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase. Breast Cancer Res Treat Mar 19, 2010 [Epub ahead of print]

35.

Berstein LM, Boyarkina MP, Tsyrlina EV, Turkevich EA, Semiglazov VF (2010) More favorable progesterone receptor phenotype of breast cancer in diabetics treated with metformin. Med Oncol May 20, 2010 [Epub ahead of print]

36.

Erdemoglu E, Güney M, Giray SG, Take G, Mungan T (2009) Effects of metformin on mammalian target of rapamycin in a mouse model of endometrial hyperplasia. Eur J Obstet Gynecol Reprod Biol 145:195–199PubMedCrossRef

37.

Shackelford DB, Shaw RJ (2009) The LKB1–AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 9:563–575PubMedCrossRef

38.

Leverve XM, Guigas B, Detaille D, Batandier C, Koceir EA, Chauvin C, Fontaine E, Wiernsperger NF (2003) Mitochondrial metabolism and type-2 diabetes: a specific target of metformin. Diabetes Metab 29(4 Pt 2):6S88–6S94PubMedCrossRef

39.

Kalender A, Selvaraj A, Kim SY, Gulati P, Brûlé S, Viollet B, Kemp BE, Bardeesy N, Dennis P, Schlager JJ, Marette A, Kozma SC, Thomas G (2010) Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab 11(5):390–401PubMedCrossRef

40.

Zakikhani M, Blouin MJ, Piura E, Pollak MN (2010) Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res Treat Feb 5, 2010 [Epub ahead of print]

41.

Rogers NH, Witczak CA, Hirshman MF, Goodyear LJ, Greenberg AS (2009) Estradiol stimulates Akt, AMP-activated protein kinase (AMPK) and TBC1D1/4, but not glucose uptake in rat soleus. Biochem Biophys Res Commun 382:646–650PubMedCrossRef

42.

Nath-Sain S, Marignani PA (2009) LKB1 catalytic activity contributes to estrogen receptor alpha signaling. Mol Biol Cell 20:2785–2795PubMedCrossRef

43.

Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE, Thor AD (2009) Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 8:2031–2040PubMedCrossRef

44.

Lefranc F, Facchini V, Kiss R (2007) Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas. Oncologist 2(12):1395–1403CrossRef

45.

Takemura Y, Osuga Y, Yoshino O, Hasegawa A, Hirata T, Hirota Y, Nose E, Morimoto C, Harada M, Koga K, Tajima T, Yano T, Taketani Y (2007) Metformin suppresses interleukin (IL)-1beta-induced IL-8 production, aromatase activation, and proliferation of endometriotic stromal cells. J Clin Endocrinol Metab 92:3213–3218PubMedCrossRef

46.

Santner SJ, Pauley RJ, Tait L, Kaseta J, Santen RJ (1997) Aromatase activity and expression in breast cancer and benign breast tissue stromal cells. J Clin Endocrinol Metab 82:200–208PubMedCrossRef

47.

Rice S, Pellatt L, Ramanathan K, Whitehead SA, Mason HD (2009) Metformin inhibits aromatase via an ERK (extracellular signal-regulated kinase)—mediated pathway. Endocrinology 150:4794–4801PubMedCrossRef

48.

Hu Y, Ghosh S, Amleh A, Yue W, Lu Y, Katz A, Li R (2005) Modulation of aromatase expression by BRCA1: a possible link to tissue-specific tumor suppression. Oncogene 24(56):8343–8348PubMedCrossRef

49.

Fan S, Meng Q, Auborn K, Carter T, Rosen EM (2006) BRCA1 and BRCA2 as molecular targets for phytochemicals indole-3-carbinol and genistein in breast and prostate cancer cells. Br J Cancer 94:407–426PubMedCrossRef

50.

Ivanov VG, Tsyrlina EV, Kovalenko IG, Poroshina TE, Gamaiunova VB, Malysheva SA, Zhil’tsova EK, Barash NIu, Shcherbakova EB, Semiglazov VF, Bershteĭn LM (2006) [Correlation of hormone-metabolic status in breast cancer with effectiveness of adjuvant hormone therapy] Vopr Onkol 52: 150–154 (in Russian)

51.

Johansson H, Gandini S, Guerrieri-Gonzaga A, Iodice S, Ruscica M, Bonanni B, Gulisano M, Magni P, Formelli F, Decensi A (2008) Effect of fenretinide and low-dose tamoxifen on insulin sensitivity in premenopausal women at high risk for breast cancer. Cancer Res 68:9512–9518PubMedCrossRef

52.

Gonzalez-Angulo AM, Meric-Bernstam F (2010) Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res 16(6):1695–1700PubMedCrossRef

53.

Stambolic V, Woodgett JR, Fantus IG, Pritchard KI, Goodwin PJ (2009) Utility of metformin in breast cancer treatment, is neoangiogenesis a risk factor? Breast Cancer Res Treat 114(2):387–389PubMedCrossRef

54.

Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA, Bae-Jump VL (2010) Metformin is a potent inhibitor of endometrial cancer cell proliferation—implications for a novel treatment strategy. Gynecol Oncol 116(1):92–98PubMedCrossRef

55.

Lalau JD, Lacroix C (2003) Measurement of metformin concentration in erythrocytes: clinical implications. Diabetes Obes Metab 5(2):93–98PubMedCrossRef

56.

Wilcock C, Bailey CJ (1994) Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica 24:49–57PubMedCrossRef

57.

Kisanga ER, Gjerde J, Guerrieri-Gonzaga A, Pigatto F, Pesci-Feltri A, Robertson C, Serrano D, Pelosi G, Decensi A, Lien EA (2004) Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial. Clin Cancer Res 10:2336–2343PubMedCrossRef

58.

Phoenix KN, Vumbaca F, Claffey KP (2009) Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model breast cancer. Res Treat 113(1):101–111CrossRef

59.

Hadad SM, Appleyard V, Thompson AM (2009) Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model. Breast Cancer Res Treat 114(2):391PubMedCrossRef

Title: Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells
Authors: Lev M. Berstein
Wei Yue
Ji-Ping Wang
Richard J. Santen
Publication date: 01-07-2011
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-010-1072-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2011

NBS1 8360G > C polymorphism is associated with breast cancer risk was not credible: appraisal of a recent meta-analysis

Value of post-operative reassessment of estrogen receptor α expression following neoadjuvant chemotherapy with or without gefitinib for estrogen receptor negative breast cancer

High estrogen receptor expression in early breast cancer: chemotherapy needed to improve RFS?

Glycodelin expression associates with differential tumour phenotype and outcome in sporadic and familial non-BRCA1/2 breast cancer patients

Signaling mechanism of cell adhesion molecules in breast cancer metastasis: potential therapeutic targets

Are polymorphisms of the ataxia telangiectasia mutated gene associated with breast cancer risk?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer